Cell Line Development Market by Product, Application, Type of Cell Lines and Source - Global Industry Analysis and Forecast to 2022
Cell Line Development Market from Qurate’s Repository provides detailed information, in-depth analysis, and forecast which is developed by a team of experts and professionals
(EMAILWIRE.COM, August 20, 2018 ) Industry Trend Analysis
In 2012, the global cell line development market was evaluated approximately USD 1.92 billion and is anticipated to reach around USD 6.41 billion while maintaining a compound annual growth rate (CAGR) of 11.44% during the forecast period owing to rising demand for effective therapeutics, technological advancements, and monoclonal antibodies in cancer treatment field. The patent ending of megahit drugs like Abilify, Lantus, Androgel, and Namenda are anticipated to encourage the admission of new biosimilars. In recent period averagely, approximately 15 fresh proteins counting recombinant and therapeutic are being permitted by the United States Food and Drug Administration (FDA) yearly. Hence, elevated demand for innovative vaccines, drugs, therapeutic proteins, and biosimilars is anticipated to fuel the expansion of the cell line development market during the forecast years. Additionally, rising vaccine manufacturing, rising healthcare spending levels, acceptance of regenerative drugs and increase in funding concerning to research and development in the biotechnology market are some of the factors likely to drive future growth of the global market.
Request Sample Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-CMR-HnM-54898
Type Outlook and Trend Analysis
Depending on the type, the market is classified into recombinant, hybridomas, primary, and continuous. Since 2014, recombinant was the major revenue rendering section owing to its superior pertinence in biologics production, protein interactions and gene activation above traditional cell assay methods. Moreover, increasing demand for toxicity testing and drug screening are anticipated to boost growth for the segment. Hybridomas sectional growth is anticipated to be in synchronization with the recombinant section largely due to the ability of large-scale incessant antibody production.
Product Outlook and Trend Analysis
In 2014, reagents and media ruled the global market concerning revenue. Rising bioproduction demanding reagents and media, right from incubation until line preservation and price exhaustive nature are the driving factors during the forecast years. Reagents utilized are attachments and matrix factors, antibiotics, freezing and dissociation reagents, miscellaneous reagents, biological buffers, and cell separation. Nutrients which are necessary for proper growth of the growing cells, Salts, and media are active in rendering that. MEM media, DMEM media, RPMI media, medium 199, Hans F-10 media, and other classical ones are frequently utilized media in cell growth.
Source Outlook and Trend Analysis
In 2014, the mammalian source for product improvement ruled the global demand owing to rising implementation rates for the monoclonal antibodies production and its capability to articulate complex proteins like human beings. Additionally, improved expression systems, as well as technology for mammalian cell source expansion, are anticipated to boost the industry growth. There are around 4,000 mammalian lines existing and research is going on for the advent of few more.
Application Outlook and Trend Analysis
The applications segment includes the production of monoclonal antibodies, vaccines, research, and bioproduction; tissue engineering; and drug discovery toxicity testing. The products have key application in bioproduction including therapeutic proteins, vaccines, and other biologics production. Additionally, an increase in research and development activities, the advent of biosimilars as well as accessibility of technologically superior procedures for large-scale manufacturing of biologics is anticipated to boost the expansion of this application section in future.
Regional Outlook and Trend Analysis
In 2014, North American cell line development regional market was the leading with revenues of around USD 800 million. The existence of advanced medical infrastructure, encouraging government initiatives concerning to development of the product, and growing awareness regarding the curative application of monoclonal antibodies in the treatment of cancer are a few major driving factors. Asia Pacific regional market is projected to experience productive CAGR during the forecast period owing to the existence of high unused opportunities along with speedily rising awareness among patients about effective treatments for cancer as well as increasing trend of research outsourcing from developing countries like China and India.
Competitive Outlook and Trend Analysis
The key industry participants in the global cell line development market include Lonza Group AG, Selexis SA, Sartorius AG, Thermo Fisher Scientific Inc., GE Healthcare, American Type Culture Collection (ATCC), European Collection of Cell Cultures (ECACC), Corning Inc., Sigma-Aldrich Corporation, and WuXi AppTec Inc. The global market is characteristically competitive noticed by high market rivalries. Market players are determined to achieve competitive benefit by exploring the available unused opportunities.
Customization Enquiry@ https://www.qurateresearch.com/report/customize/HnM/QBI-CMR-HnM-54898
The global cell line development market is segmented as follows –
By Product
Reagents and Media
Accessories and Consumables
Equipment
Centrifuges
Incubators
Storage Equipment
Bioreactors
Microscopes
By Application
Bioproduction
Toxicity Testing
Drug Discovery
Research
Tissue Engineering
By Type of Cell Lines
Continuous Cell Lines
Recombinant Cell Lines
Primary Cell Lines
Hybridomas
By Source:
Non-Mammalian Cell Line
Amphibians
Insects
Mammalian Cell Line
By Region
North America
U.S
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia Pacific
Rest of the World
Brazil
South Africa
Saudi Arabia
United Arab Emirates
Others
Some of the key questions answered by the report are:
What was the market size in 2012 and forecast from 2013 to 2022?
What will be the industry market growth from 2013 to 2022?
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
What are the major segments leading the market growth and why?
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Click on the link to Buy Now@ https://www.qurateresearch.com/report/buy/HnM/QBI-CMR-HnM-54898
In 2012, the global cell line development market was evaluated approximately USD 1.92 billion and is anticipated to reach around USD 6.41 billion while maintaining a compound annual growth rate (CAGR) of 11.44% during the forecast period owing to rising demand for effective therapeutics, technological advancements, and monoclonal antibodies in cancer treatment field. The patent ending of megahit drugs like Abilify, Lantus, Androgel, and Namenda are anticipated to encourage the admission of new biosimilars. In recent period averagely, approximately 15 fresh proteins counting recombinant and therapeutic are being permitted by the United States Food and Drug Administration (FDA) yearly. Hence, elevated demand for innovative vaccines, drugs, therapeutic proteins, and biosimilars is anticipated to fuel the expansion of the cell line development market during the forecast years. Additionally, rising vaccine manufacturing, rising healthcare spending levels, acceptance of regenerative drugs and increase in funding concerning to research and development in the biotechnology market are some of the factors likely to drive future growth of the global market.
Request Sample Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-CMR-HnM-54898
Type Outlook and Trend Analysis
Depending on the type, the market is classified into recombinant, hybridomas, primary, and continuous. Since 2014, recombinant was the major revenue rendering section owing to its superior pertinence in biologics production, protein interactions and gene activation above traditional cell assay methods. Moreover, increasing demand for toxicity testing and drug screening are anticipated to boost growth for the segment. Hybridomas sectional growth is anticipated to be in synchronization with the recombinant section largely due to the ability of large-scale incessant antibody production.
Product Outlook and Trend Analysis
In 2014, reagents and media ruled the global market concerning revenue. Rising bioproduction demanding reagents and media, right from incubation until line preservation and price exhaustive nature are the driving factors during the forecast years. Reagents utilized are attachments and matrix factors, antibiotics, freezing and dissociation reagents, miscellaneous reagents, biological buffers, and cell separation. Nutrients which are necessary for proper growth of the growing cells, Salts, and media are active in rendering that. MEM media, DMEM media, RPMI media, medium 199, Hans F-10 media, and other classical ones are frequently utilized media in cell growth.
Source Outlook and Trend Analysis
In 2014, the mammalian source for product improvement ruled the global demand owing to rising implementation rates for the monoclonal antibodies production and its capability to articulate complex proteins like human beings. Additionally, improved expression systems, as well as technology for mammalian cell source expansion, are anticipated to boost the industry growth. There are around 4,000 mammalian lines existing and research is going on for the advent of few more.
Application Outlook and Trend Analysis
The applications segment includes the production of monoclonal antibodies, vaccines, research, and bioproduction; tissue engineering; and drug discovery toxicity testing. The products have key application in bioproduction including therapeutic proteins, vaccines, and other biologics production. Additionally, an increase in research and development activities, the advent of biosimilars as well as accessibility of technologically superior procedures for large-scale manufacturing of biologics is anticipated to boost the expansion of this application section in future.
Regional Outlook and Trend Analysis
In 2014, North American cell line development regional market was the leading with revenues of around USD 800 million. The existence of advanced medical infrastructure, encouraging government initiatives concerning to development of the product, and growing awareness regarding the curative application of monoclonal antibodies in the treatment of cancer are a few major driving factors. Asia Pacific regional market is projected to experience productive CAGR during the forecast period owing to the existence of high unused opportunities along with speedily rising awareness among patients about effective treatments for cancer as well as increasing trend of research outsourcing from developing countries like China and India.
Competitive Outlook and Trend Analysis
The key industry participants in the global cell line development market include Lonza Group AG, Selexis SA, Sartorius AG, Thermo Fisher Scientific Inc., GE Healthcare, American Type Culture Collection (ATCC), European Collection of Cell Cultures (ECACC), Corning Inc., Sigma-Aldrich Corporation, and WuXi AppTec Inc. The global market is characteristically competitive noticed by high market rivalries. Market players are determined to achieve competitive benefit by exploring the available unused opportunities.
Customization Enquiry@ https://www.qurateresearch.com/report/customize/HnM/QBI-CMR-HnM-54898
The global cell line development market is segmented as follows –
By Product
Reagents and Media
Accessories and Consumables
Equipment
Centrifuges
Incubators
Storage Equipment
Bioreactors
Microscopes
By Application
Bioproduction
Toxicity Testing
Drug Discovery
Research
Tissue Engineering
By Type of Cell Lines
Continuous Cell Lines
Recombinant Cell Lines
Primary Cell Lines
Hybridomas
By Source:
Non-Mammalian Cell Line
Amphibians
Insects
Mammalian Cell Line
By Region
North America
U.S
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia Pacific
Rest of the World
Brazil
South Africa
Saudi Arabia
United Arab Emirates
Others
Some of the key questions answered by the report are:
What was the market size in 2012 and forecast from 2013 to 2022?
What will be the industry market growth from 2013 to 2022?
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
What are the major segments leading the market growth and why?
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Click on the link to Buy Now@ https://www.qurateresearch.com/report/buy/HnM/QBI-CMR-HnM-54898
Contact Information:
Qurate Business Intelligence
Nehal Chinoy
Tel: +919881074592
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Qurate Business Intelligence
Nehal Chinoy
Tel: +919881074592
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results